药康生物首次公开发行股票的发行费用总额为1.00亿元，其中，保荐承销费8278.75万元。 (责任编辑：马欣) 中国经济网北京1月19日讯 药康生物(688046.SH)今日股价下跌，截至收盘，该股报18.14元，跌幅 4.07%。 药康生物于2022年4月25日在上交所科创板上市，发行价格为22.53元/股，公开发行股票数量5000万 股，保荐机构（主承销商）为华泰联合证券有限责任公司，保荐代表人为季李华、洪捷超。该股目前处 于破发状态。 药康生物首次公开发行股票募集资金总额为11.27亿元，募集资金净额为10.26亿元。药康生物最终募集 资金净额比原计划多2.06亿元。药康生物于2022年4月18日披露的招股说明书显示，该公司拟募集资金 8.20亿元，分别用于模式动物小鼠研发繁育一体化基地建设项目、真实世界动物模型研发及转化平台建 设项目。 ...

证券日报网讯 1月16日，药康生物在互动平台回答投资者提问时表示，公司已组建约40人海外BD团 队，覆盖北美、欧洲及亚太三大区域，在超20个国家实现销售。公司在欧洲区域设有办公室，以直销为 主，覆盖德国、英国、法国、瑞士、意大利等国家，2025年欧洲区域增长良好，市场渗透率持续提升。 具体财务数据请关注公司相关公告。 ...

（文章来源：每日经济新闻） 药康生物（688046.SH）1月16日在投资者互动平台表示，公司已组建约40人海外BD团队，覆盖北美、 欧洲及亚太三大区域，在超20个国家实现销售。公司在欧洲区域设有办公室，以直销为主，覆盖德国、 英国、法国、瑞士、意大利等国家，2025年欧洲区域增长良好，市场渗透率持续提升。具体财务数据请 关注公司相关公告。 每经AI快讯，有投资者在投资者互动平台提问：请问公司近年是否存在向欧盟出口或销售的相关业 务？如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售 主要通过哪种方式实现？是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进 行销售，或通过第三方贸易商、代理商转销至欧盟市场？ ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. specializes in the research, production, and sales of laboratory mouse models and related technical services, with a total market value of 7.249 billion yuan as of January 9 [1] - The company's main business revenue composition includes: commercial mouse model sales (55.36%), functional efficacy (23.46%), custom breeding (11.32%), model creation (7.06%), and import-export agency and others (2.70%) [1] - As of January 9, Yaokang's stock price increased by 5.05% to 17.68 yuan per share, with a trading volume of 77.5669 million yuan and a turnover rate of 1.10% [1] Group 2 - The top circulating shareholder of Yaokang is the Nuoan Fund, which reduced its holdings in the Nuoan Pioneer Mixed A Fund (320003) by 265,200 shares, now holding 5.0687 million shares, accounting for 1.24% of circulating shares [2] - The Nuoan Pioneer Mixed A Fund has achieved a year-to-date return of 7.4% and a one-year return of 48.16%, ranking 661 out of 8,827 and 2,116 out of 8,084 respectively [2] - The fund manager, Yang Gu, has a tenure of 19 years and 327 days, with the fund's total asset size at 5.804 billion yuan and a best return of 1,088.72% during his tenure [3]

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Core Viewpoint - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (referred to as "Yaokang Bio") is partially exiting its investment in Jiangxi Zhonghong Boyuan Biotechnology Co., Ltd. through a directed capital reduction, returning an investment of RMB 10 million and receiving a corresponding compensation for fund occupation at an annual interest rate of 5% [2][3]. Summary by Sections 1. Overview of Related Transactions - As of the announcement date, Yaokang Bio has invested RMB 70 million in Jiangxi Zhonghong, holding 22.8261% of its shares. The company will reduce its investment through a directed capital reduction, receiving RMB 10 million back and adjusting its shareholding to 20.2247% [4][10]. - If Jiangxi Zhonghong agrees to allow other shareholders to also reduce their investments by a total of RMB 15 million, Yaokang Bio's shareholding will adjust to 20.9302% [4][10]. 2. Related Party Information - Jiangxi Zhonghong is classified as a related party due to Yaokang Bio's shareholding [6]. 3. Transaction Pricing - The historical total investment by Yaokang Bio is RMB 70 million, and the capital reduction of RMB 10 million corresponds to a shareholding reduction of 2.6014% [10]. - The compensation for fund occupation is calculated to be RMB 1,657,534.25, based on the formula provided [10][12]. 4. Necessity and Impact of the Transaction - The transaction aligns with the overall development strategy and operational plans of the company, and it is not expected to negatively impact the financial status or operational results of Yaokang Bio [21]. 5. Review Procedures - The independent directors and the audit committee have approved the transaction, confirming that the pricing is fair and does not harm the interests of other shareholders [22][23][24].

重要内容提示： 江苏集萃药康生物科技股份有限公司（以下简称"药康生物"或"公司"） 前期向江西中洪博元生物技术有限公司（以下简称"江西中洪"）投资人民币 7,000 万元；经各方友好协商，一致同意药康生物通过定向减资方式部分退出投资。江 西中洪同意向公司返还减资额 1,000 万元，并支付对应资金占用补偿（年利率 5%）， 以体现历史溢价投资合理退出的资金成本。 证券代码：688046 证券简称：药康生物 公告编号：2026-001 江苏集萃药康生物科技股份有限公司 关于参股公司回购公司所持股份暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次交易构成关联交易，未构成重大资产重组，交易实施不存在重大法 律障碍。 本次交易已经公司 2026 年第一次独立董事专门会议、第二届董事会审计 委员会第十一次会议和第二届董事会第十五次会议审议通过，无需提交股东会审 议。本次交易事项尚需交易各方完成各自审议程序方能生效，请投资者注意投资 风险。 一、关联交易概述 截至本公告披露之日，公司已向江西中洪投资 7,000 ...

药康生物公告称，公司前期向江西中洪投资7000万元，现双方协商，公司拟通过定向减资方式部分退出 投资。江西中洪同意返还1000万元减资额，并支付对应资金占用补偿（年利率5%）。公司持股比例将 从22.8261%降至20.2247%；若苏州济康和苏州国发同步退出1500万元，公司持股比例降至20.9302%。 本次交易构成关联交易，不构成重大资产重组，尚需各方完成审议程序。过去12个月内，双方累计关联 交易168.11万元。 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].